{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:55:21Z","timestamp":1791618921307,"version":"4.3.4"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K23HL164901"],"award-info":[{"award-number":["K23HL164901"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10553-8","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:52:00Z","timestamp":1757454720000},"page":"1353-1360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of pulmonary hypertension in\u00a0heart failure with preserved ejection fraction"],"prefix":"10.1007","volume":"30","author":[{"given":"Jenny Jia Ling","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh N. V.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"10553_CR1","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","volume":"81","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE (2023) Heart failure with preserved ejection fraction: JACC Scientific Statement. J Am Coll Cardiol 81:1810\u20131834","journal-title":"J Am Coll Cardiol"},{"key":"10553_CR2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cardfail.2020.08.008","volume":"26","author":"YNV Reddy","year":"2020","unstructured":"Reddy YNV et al (2020) Characterization of the progression from ambulatory to hospitalized heart failure with preserved ejection fraction. J Card Fail 26:919\u2013928","journal-title":"J Card Fail"},{"key":"10553_CR3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ejhf.2747","volume":"25","author":"K Omote","year":"2023","unstructured":"Omote K et al (2023) Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea. Eur J Heart Fail 25:185\u2013196","journal-title":"Eur J Heart Fail"},{"key":"10553_CR4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCRESAHA.118.313832","volume":"124","author":"YNV Reddy","year":"2019","unstructured":"Reddy YNV et al (2019) The \u03b2-adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction. Circ Res 124:306\u2013314","journal-title":"Circ Res"},{"key":"10553_CR5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCHEARTFAILURE.114.002114","volume":"8","author":"MJ Andersen","year":"2015","unstructured":"Andersen MJ et al (2015) Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction. Circ Heart Fail 8:542\u2013550","journal-title":"Circ Heart Fail"},{"key":"10553_CR6","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.jacc.2024.08.061","volume":"84","author":"YNV Reddy","year":"2024","unstructured":"Reddy YNV et al (2024) Clinical implications of pretest probability of HFpEF on outcomes in precapillary pulmonary hypertension. J Am Coll Cardiol 84:2196\u20132210","journal-title":"J Am Coll Cardiol"},{"key":"10553_CR7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","volume":"138","author":"YNV Reddy","year":"2018","unstructured":"Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA (2018) A Simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 138:861\u2013870","journal-title":"Circulation"},{"key":"10553_CR8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","volume":"135","author":"M Obokata","year":"2017","unstructured":"Obokata M et al (2017) Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation 135:825\u2013838","journal-title":"Circulation"},{"key":"10553_CR9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamacardio.2022.1916","volume":"7","author":"YNV Reddy","year":"2022","unstructured":"Reddy YNV et al (2022) Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea. JAMA Cardiol 7:891\u2013899","journal-title":"JAMA Cardiol"},{"key":"10553_CR10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCHEARTFAILURE.115.002161","volume":"8","author":"M Santos","year":"2015","unstructured":"Santos M et al (2015) E\/e\u2019 ratio in patients with unexplained dyspnea: lack of accuracy in estimating left ventricular filling pressure. Circ Heart Fail 8:749\u2013756","journal-title":"Circ Heart Fail"},{"key":"10553_CR11","doi-asserted-by":"publisher","unstructured":"Verbrugge FH\u00a0et al\u00a0(2022) Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. Eur Heart J\u00a0ehab911\u00a0https:\/\/doi.org\/10.1093\/eurheartj\/ehab911","DOI":"10.1093\/eurheartj\/ehab911"},{"key":"10553_CR12","doi-asserted-by":"crossref","unstructured":"Reddy YNV, Tada A, Obokata M, Carter RE, Kaye DM, Handoko ML, Andersen MJ, Sharma K, Tedford RJ, Redfield MM, Borlaug BA (2025) Evidence-based application of natriuretic peptides in the evaluation of chronic heart failure with preserved ejection fraction in the ambulatory outpatient setting. Circulation 151(14):976\u2013989","DOI":"10.1161\/CIRCULATIONAHA.124.072156"},{"key":"10553_CR13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA (2017) Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 136:6\u201319","journal-title":"Circulation"},{"key":"10553_CR14","doi-asserted-by":"crossref","first-page":"e005711","DOI":"10.1161\/CIRCIMAGING.116.005711","volume":"10","author":"ACMJ van Riel","year":"2017","unstructured":"van Riel ACMJ et al (2017) Accuracy of echocardiography to estimate pulmonary artery pressures with exercise: a simultaneous invasive-noninvasive comparison. Circ Cardiovasc Imaging 10:e005711","journal-title":"Circ Cardiovasc Imaging"},{"key":"10553_CR15","doi-asserted-by":"crossref","first-page":"1901617","DOI":"10.1183\/13993003.01617-2019","volume":"55","author":"M Obokata","year":"2020","unstructured":"Obokata M et al (2020) Noninvasive evaluation of pulmonary artery pressure during exercise: the importance of right atrial hypertension. Eur Respir J 55:1901617","journal-title":"Eur Respir J"},{"key":"10553_CR16","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.1464","volume":"21","author":"YNV Reddy","year":"2019","unstructured":"Reddy YNV et al (2019) Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction. Eur J Heart Fail 21:891\u2013900","journal-title":"Eur J Heart Fail"},{"key":"10553_CR17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Galie","year":"2016","unstructured":"Galie N et al (2016) 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67\u2013119","journal-title":"Eur Heart J"},{"key":"10553_CR18","doi-asserted-by":"crossref","first-page":"2401324","DOI":"10.1183\/13993003.01324-2024","volume":"64","author":"G Kovacs","year":"2024","unstructured":"Kovacs G et al (2024) Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J 64:2401324","journal-title":"Eur Respir J"},{"key":"10553_CR19","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.cardfail.2023.06.009","volume":"29","author":"J Grinstein","year":"2023","unstructured":"Grinstein J et al (2023) Variation in hemodynamic assessment and interpretation: a call to standardize the right heart catheterization. J Card Fail 29:1507\u20131518","journal-title":"J Card Fail"},{"key":"10553_CR20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamacardio.2018.0318","volume":"3","author":"YNV Reddy","year":"2018","unstructured":"Reddy YNV, El-Sabbagh A, Nishimura RA (2018) Comparing pulmonary arterial wedge pressure and left ventricular end diastolic pressure for assessment of left-sided filling pressures. JAMA Cardiol 3:453\u2013454","journal-title":"JAMA Cardiol"},{"key":"10553_CR21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.21693\/1933-088X-22.3.130","volume":"22","author":"YNV Reddy","year":"2023","unstructured":"Reddy YNV (2023) Heart failure with preserved ejection fraction and the diagnosis of pulmonary hypertension. Adv Pulm Hypertens 22:130\u2013133","journal-title":"Adv Pulm Hypertens"},{"key":"10553_CR22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0735-1097(94)90764-1","volume":"23","author":"OA Smiseth","year":"1994","unstructured":"Smiseth OA, Thompson CR, Ling H, Robinson M, Miyagishima RT (1994) Juxtacardiac pleural pressure during positive end-expiratory pressure ventilation: an intraoperative study in patients with open pericardium. J Am Coll Cardiol 23:753\u2013758","journal-title":"J Am Coll Cardiol"},{"key":"10553_CR23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jamacardio.2018.0128","volume":"3","author":"RR Vanderpool","year":"2018","unstructured":"Vanderpool RR, Saul M, Nouraie M, Gladwin MT, Simon MA (2018) Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol 3:298\u2013306","journal-title":"JAMA Cardiol"},{"key":"10553_CR24","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1161\/CIRCULATIONAHA.122.059486","volume":"145","author":"BA Borlaug","year":"2022","unstructured":"Borlaug BA et al (2022) Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure. Circulation 145:1592\u20131604","journal-title":"Circulation"},{"key":"10553_CR25","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1093\/eurheartj\/ehy331","volume":"39","author":"TM Gorter","year":"2018","unstructured":"Gorter TM, Obokata M, Reddy YNV, Melenovsky V, Borlaug BA (2018) Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease. Eur Heart J 39:2825\u20132835","journal-title":"Eur Heart J"},{"key":"10553_CR26","doi-asserted-by":"crossref","first-page":"2401344","DOI":"10.1183\/13993003.01344-2024","volume":"64","author":"BA Maron","year":"2024","unstructured":"Maron BA et al (2024) Pulmonary hypertension associated with left heart disease. Eur Respir J 64:2401344","journal-title":"Eur Respir J"},{"key":"10553_CR27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1164\/rccm.202402-0359VP","volume":"210","author":"SG Rayner","year":"2024","unstructured":"Rayner SG, Tedford RJ, Leary PJ, Mak S, Houston BA (2024) \u2018This patient needs a doctor, not a guideline!\u2019 The zone of uncertainty in pulmonary arterial wedge pressure measurement. Am J Respir Crit Care Med 210:712\u2013714","journal-title":"Am J Respir Crit Care Med"},{"key":"10553_CR28","doi-asserted-by":"crossref","unstructured":"Reddy YNV, Asokan AK, Frantz RP, Hemnes A, Hassoun PM, Barnard J, Horn E, Leopold JA, Rischard F, Rosenzweig EB, Hill NS, Erzurum SC, Beck GJ, Finet JE, Grunig G, Jellis CL, Mathai SC, Simpson CE, Tang WHW, Nair KS, Borlaug BA (2025) PVDOMICS study group. Metabolomic evidence of biological overlap with HFpEF in a subset of pulmonary arterial hypertension. Am J Respir Crit Care Med","DOI":"10.1164\/rccm.202501-0034OC"},{"key":"10553_CR29","doi-asserted-by":"publisher","unstructured":"Reddy YNV et al (2025) Left heart abnormalities in patients with lung disease, OSA, and chronic thromboemboli at risk for or with known pulmonary hypertension. Circ Heart Fail e012912. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.125.012912","DOI":"10.1161\/CIRCHEARTFAILURE.125.012912"},{"key":"10553_CR30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cardfail.2017.11.003","volume":"24","author":"W Huang","year":"2018","unstructured":"Huang W, Oliveira RKF, Lei H, Systrom DM, Waxman AB (2018) Pulmonary vascular resistance during exercise predicts long-term outcomes in heart failure with preserved ejection fraction. J Card Fail 24:169\u2013176","journal-title":"J Card Fail"},{"key":"10553_CR31","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/s41591-024-03140-1","volume":"30","author":"YNV Reddy","year":"2024","unstructured":"Reddy YNV et al (2024) An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score. Nat Med 30:2258\u20132264","journal-title":"Nat Med"},{"key":"10553_CR32","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2016.09.942","volume":"68","author":"TR Assad","year":"2016","unstructured":"Assad TR et al (2016) Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension. J Am Coll Cardiol 68:2525\u20132536","journal-title":"J Am Coll Cardiol"},{"key":"10553_CR33","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","volume":"68","author":"CF Opitz","year":"2016","unstructured":"Opitz CF et al (2016) Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 68:368\u2013378","journal-title":"J Am Coll Cardiol"},{"key":"10553_CR34","doi-asserted-by":"crossref","unstructured":"McLaughlin VV\u00a0et al\u00a0(2019)\u00a0Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: results from the AMBITION trial. J Heart Lung Transplant Off Publ Int Soc Heart Transplant\u00a038:1286\u20131295","DOI":"10.1016\/j.healun.2019.09.010"},{"key":"10553_CR35","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.chest.2023.10.037","volume":"165","author":"K Kearney","year":"2024","unstructured":"Kearney K et al (2024) Impact of left heart disease risk factors on outcomes in pulmonary arterial hypertension therapy. Chest 165:967\u2013977","journal-title":"Chest"},{"key":"10553_CR36","doi-asserted-by":"publisher","unstructured":"Rosenkranz S\u00a0et al\u00a0(2024) Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: data from interventional clinical trials. J Heart Lung Transplant Off Publ Int Soc Heart Transplant\u00a0S1053\u20132498(24)01807\u20132.\u00a0https:\/\/doi.org\/10.1016\/j.healun.2024.08.018","DOI":"10.1016\/j.healun.2024.08.018"},{"key":"10553_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3319","author":"VV McLaughlin","year":"2024","unstructured":"McLaughlin VV et al (2024) Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.3319","journal-title":"Eur J Heart Fail"},{"key":"10553_CR38","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","volume":"137","author":"AU Fayyaz","year":"2018","unstructured":"Fayyaz AU et al (2018) Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation 137:1796\u20131810","journal-title":"Circulation"},{"key":"10553_CR39","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1093\/eurheartj\/ehz626","volume":"40","author":"M Obokata","year":"2019","unstructured":"Obokata M et al (2019) The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction. Eur Heart J 40:3707\u20133717","journal-title":"Eur Heart J"},{"key":"10553_CR40","doi-asserted-by":"publisher","unstructured":"Sera F\u00a0et al\u00a0(2022)\u00a0Pulmonary hypertension with a precapillary component in heart failure with preserved ejection fraction. Heart Br Card Soc\u00a0heartjnl-2022\u2013321565.\u00a0https:\/\/doi.org\/10.1136\/heartjnl-2022-321565","DOI":"10.1136\/heartjnl-2022-321565"},{"key":"10553_CR41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ccm.2020.11.002","volume":"42","author":"YNV Reddy","year":"2021","unstructured":"Reddy YNV, Borlaug BA (2021) Pulmonary hypertension in left heart disease. Clin Chest Med 42:39\u201358","journal-title":"Clin Chest Med"},{"key":"10553_CR42","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJM199312023292317","volume":"329","author":"K Yamamoto","year":"1993","unstructured":"Yamamoto K, Ikeda U, Shimada K (1993) Endothelin production in mitral stenosis. N Engl J Med 329:1740\u20131741","journal-title":"N Engl J Med"},{"key":"10553_CR43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000501100","volume":"143","author":"MA Chowdhury","year":"2019","unstructured":"Chowdhury MA et al (2019) Endothelin 1 is associated with heart failure hospitalization and long-term mortality in patients with heart failure with preserved ejection fraction and pulmonary hypertension. Cardiology 143:124\u2013133","journal-title":"Cardiology"},{"key":"10553_CR44","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(95)91504-4","volume":"346","author":"W Kiowski","year":"1995","unstructured":"Kiowski W et al (1995) Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346:732\u2013736","journal-title":"Lancet"},{"key":"10553_CR45","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1161\/CIRCHEARTFAILURE.110.960864","volume":"4","author":"D Aronson","year":"2011","unstructured":"Aronson D, Eitan A, Dragu R, Burger AJ (2011) Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. Circ Heart Fail 4:644\u2013650","journal-title":"Circ Heart Fail"},{"key":"10553_CR46","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1093\/eurheartj\/ehac184","volume":"43","author":"K Omote","year":"2022","unstructured":"Omote K et al (2022) Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications. Eur Heart J 43:3417\u20133431","journal-title":"Eur Heart J"},{"key":"10553_CR47","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","volume":"40","author":"M Obokata","year":"2019","unstructured":"Obokata M, Reddy YNV, Melenovsky V, Pislaru S, Borlaug BA (2019) Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J 40:689\u2013697","journal-title":"Eur Heart J"},{"key":"10553_CR48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","volume":"568","author":"GG Schiattarella","year":"2019","unstructured":"Schiattarella GG et al (2019) Nitrosative stress drives heart failure with preserved ejection fraction. Nature 568:351\u2013356","journal-title":"Nature"},{"key":"10553_CR49","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/CIRCRESAHA.123.323119","volume":"133","author":"V Agrawal","year":"2023","unstructured":"Agrawal V et al (2023) Myeloid cell derived IL1\u03b2 contributes to pulmonary hypertension in HFpEF. Circ Res 133:885\u2013898","journal-title":"Circ Res"},{"key":"10553_CR50","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2020.07.009","volume":"76","author":"YNV Reddy","year":"2020","unstructured":"Reddy YNV, Obokata M, Verbrugge FH, Lin G, Borlaug BA (2020) Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation. J Am Coll Cardiol 76:1051\u20131064","journal-title":"J Am Coll Cardiol"},{"key":"10553_CR51","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/CIRCULATIONAHA.124.068624","volume":"150","author":"J-R Jheng","year":"2024","unstructured":"Jheng J-R et al (2024) Skeletal muscle SIRT3 deficiency contributes to pulmonary vascular remodeling in pulmonary hypertension due to heart failure with preserved ejection fraction. Circulation 150:867\u2013883","journal-title":"Circulation"},{"key":"10553_CR52","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jchf.2019.03.021","volume":"7","author":"BA Borlaug","year":"2019","unstructured":"Borlaug BA, Reddy YNV (2019) The role of the pericardium in heart failure: implications for pathophysiology and treatment. JACC Heart Fail 7:574\u2013585","journal-title":"JACC Heart Fail"},{"key":"10553_CR53","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1093\/eurheartj\/ehz713","volume":"40","author":"YNV Reddy","year":"2019","unstructured":"Reddy YNV et al (2019) The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction. Eur Heart J 40:3721\u20133730","journal-title":"Eur Heart J"},{"key":"10553_CR54","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/CIRCULATIONAHA.121.054858","volume":"144","author":"MK Burrage","year":"2021","unstructured":"Burrage MK et al (2021) Energetic basis for exercise-induced pulmonary congestion in heart failure with preserved ejection fraction. Circulation 144:1664\u20131678","journal-title":"Circulation"},{"key":"10553_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2930","author":"M Omar","year":"2023","unstructured":"Omar M et al (2023) Hypoxaemia in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.2930","journal-title":"Eur J Heart Fail"},{"key":"10553_CR56","doi-asserted-by":"crossref","first-page":"1701886","DOI":"10.1183\/13993003.01886-2017","volume":"51","author":"J-L Vachi\u00e9ry","year":"2018","unstructured":"Vachi\u00e9ry J-L et al (2018) Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 51:1701886","journal-title":"Eur Respir J"},{"key":"10553_CR57","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1161\/CIRCULATIONAHA.124.069340","volume":"150","author":"MM Hoeper","year":"2024","unstructured":"Hoeper MM et al (2024) Tadalafil for treatment of combined postcapillary and precapillary pulmonary hypertension in patients with heart failure and preserved ejection fraction: a randomized controlled phase 3 study. Circulation 150:600\u2013610","journal-title":"Circulation"},{"key":"10553_CR58","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","volume":"39","author":"J Bermejo","year":"2018","unstructured":"Bermejo J et al (2018) Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J 39:1255\u20131264","journal-title":"Eur Heart J"},{"key":"10553_CR59","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","volume":"7","author":"PB Adamson","year":"2014","unstructured":"Adamson PB et al (2014) Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 7:935\u2013944","journal-title":"Circ Heart Fail"},{"key":"10553_CR60","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089\u20131098","journal-title":"N Engl J Med"},{"key":"10553_CR61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","author":"SD Anker","year":"2021","unstructured":"Anker SD et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"10553_CR62","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus JA et al (2022) The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med 28:809\u2013813","journal-title":"Nat Med"},{"key":"10553_CR63","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME et al (2021) The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 27:1954\u20131960","journal-title":"Nat Med"},{"key":"10553_CR64","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","volume":"148","author":"M Packer","year":"2023","unstructured":"Packer M, Wilcox CS, Testani JM (2023) Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes. Circulation 148:354\u2013372","journal-title":"Circulation"},{"key":"10553_CR65","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","volume":"148","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA et al (2023) Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial. Circulation 148:834\u2013844","journal-title":"Circulation"},{"key":"10553_CR66","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","volume":"43","author":"C Adamson","year":"2022","unstructured":"Adamson C et al (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J 43:4406\u20134417","journal-title":"Eur Heart J"},{"key":"10553_CR67","doi-asserted-by":"publisher","unstructured":"Reddy YNV\u00a0et al\u00a0(2024)\u00a0Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction. Eur Heart J\u00a0ehae534.\u00a0https:\/\/doi.org\/10.1093\/eurheartj\/ehae534","DOI":"10.1093\/eurheartj\/ehae534"},{"key":"10553_CR68","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1161\/CIRCULATIONAHA.124.069479","volume":"149","author":"JA Naser","year":"2024","unstructured":"Naser JA et al (2024) Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction. Circulation 149:2026\u20132028","journal-title":"Circulation"},{"key":"10553_CR69","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif ME et al (2021) Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation 143:1673\u20131686","journal-title":"Circulation"},{"key":"10553_CR70","doi-asserted-by":"publisher","unstructured":"Reddy YNV\u00a0et al\u00a0(2024) Dapagliflozin and right ventricular-pulmonary vascular interaction in heart failure with preserved ejection fraction: a secondary analysis of a randomized clinical trial. JAMA Cardiol\u00a0e241914.\u00a0https:\/\/doi.org\/10.1001\/jamacardio.2024.1914","DOI":"10.1001\/jamacardio.2024.1914"},{"key":"10553_CR71","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.124.068788","volume":"150","author":"A Tada","year":"2024","unstructured":"Tada A et al (2024) Dapagliflozin enhances arterial and venous compliance during exercise in heart failure with preserved ejection fraction: insights from the CAMEO-DAPA trial. Circulation 150:997\u20131009","journal-title":"Circulation"},{"key":"10553_CR72","doi-asserted-by":"crossref","unstructured":"Doi S, Reddy YNV, Jensen MD, Smith JR, Borlaug BA (2025) Dapagliflozin and ventilatory control during exercise in heart failure with preserved ejection fraction: the CAMEO-DAPA trial. Eur Heart J 46(16):1554\u20131556","DOI":"10.1093\/eurheartj\/ehaf027"},{"issue":"24","key":"10553_CR73","doi-asserted-by":"publisher","first-page":"07897","DOI":"10.1016\/j.jacc.2024.07.013","volume":"S0735\u20131097","author":"M Packer","year":"2024","unstructured":"Packer M et al (2024) Reaffirmation of mechanistic proteomic signatures accompanying SGLT2 inhibition in patients with heart failure: a validation cohort of the EMPEROR program. J Am Coll Cardiol S0735\u20131097(24):07897\u201307905. https:\/\/doi.org\/10.1016\/j.jacc.2024.07.013","journal-title":"J Am Coll Cardiol"},{"key":"10553_CR74","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389:1069\u20131084","journal-title":"N Engl J Med"},{"key":"10553_CR75","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN et al (2024) Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 390:1394\u20131407","journal-title":"N Engl J Med"},{"issue":"24","key":"10553_CR76","doi-asserted-by":"publisher","first-page":"00469","DOI":"10.1016\/S0140-6736(24)00469-0","volume":"S0140\u20136736","author":"J Butler","year":"2024","unstructured":"Butler J et al (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet Lond Engl S0140\u20136736(24):00469. https:\/\/doi.org\/10.1016\/S0140-6736(24)00469-0","journal-title":"Lancet Lond Engl"},{"key":"10553_CR77","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","volume":"29","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA et al (2023) Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med 29:2358\u20132365","journal-title":"Nat Med"},{"key":"10553_CR78","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jacc.2025.03.530","volume":"85","author":"YNV Reddy","year":"2025","unstructured":"Reddy YNV et al (2025) Disentangling the impact of adiposity from insulin resistance in heart failure with preserved ejection fraction. J Am Coll Cardiol 85:1774\u20131788","journal-title":"J Am Coll Cardiol"},{"key":"10553_CR79","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","volume":"315","author":"DW Kitzman","year":"2016","unstructured":"Kitzman DW et al (2016) Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 315:36\u201346","journal-title":"JAMA"},{"key":"10553_CR80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","author":"M Packer","year":"2024","unstructured":"Packer M et al (2024) Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"key":"10553_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03374-z","author":"BA Borlaug","year":"2024","unstructured":"Borlaug BA et al (2024) Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-024-03374-z","journal-title":"Nat Med"},{"issue":"24","key":"10553_CR82","doi-asserted-by":"publisher","first-page":"10414","DOI":"10.1016\/j.jacc.2024.11.001","volume":"S0735\u20131097","author":"CM Kramer","year":"2024","unstructured":"Kramer CM et al (2024) Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. J Am Coll Cardiol S0735\u20131097(24):10414\u201310417. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.001","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10553_CR83","doi-asserted-by":"publisher","first-page":"08192","DOI":"10.1016\/j.jacc.2024.08.021","volume":"S0735\u20131097","author":"SD Solomon","year":"2024","unstructured":"Solomon SD et al (2024) Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure. J Am Coll Cardiol S0735\u20131097(24):08192. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.021","journal-title":"J Am Coll Cardiol"},{"key":"10553_CR84","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jchf.2019.04.019","volume":"7","author":"YNV Reddy","year":"2019","unstructured":"Reddy YNV et al (2019) Hemodynamic effects of weight loss in obesity: a systematic review and meta-analysis. JACC Heart Fail 7:678\u2013687","journal-title":"JACC Heart Fail"},{"key":"10553_CR85","doi-asserted-by":"crossref","unstructured":"Pitt B\u00a0et al\u00a0(1999)\u00a0The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med\u00a0341:709\u2013717","DOI":"10.1056\/NEJM199909023411001"},{"key":"10553_CR86","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 391:1475\u20131485","journal-title":"N Engl J Med"},{"key":"10553_CR87","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD et al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381:1609\u20131620","journal-title":"N Engl J Med"},{"key":"10553_CR88","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jchf.2021.01.015","volume":"9","author":"D Burkhoff","year":"2021","unstructured":"Burkhoff D et al (2021) Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial. JACC Heart Fail 9:360\u2013370","journal-title":"JACC Heart Fail"},{"key":"10553_CR89","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coph.2019.04.001","volume":"45","author":"CH Leo","year":"2019","unstructured":"Leo CH, Jelinic M, Ng HH, Parry LJ, Tare M (2019) Recent developments in relaxin mimetics as therapeutics for cardiovascular diseases. Curr Opin Pharmacol 45:42\u201348","journal-title":"Curr Opin Pharmacol"},{"key":"10553_CR90","unstructured":"Muslin A. Hemodynamic effects of TX45, a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients. https:\/\/esc365.escardio.org\/presentation\/302721. Accessed 15 June 2025"},{"key":"10553_CR91","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jcin.2018.09.021","volume":"12","author":"H Zhang","year":"2019","unstructured":"Zhang H et al (2019) Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure: the PADN-5 study. JACC Cardiovasc Interv 12:274\u2013284","journal-title":"JACC Cardiovasc Interv"},{"key":"10553_CR92","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","volume":"384","author":"M Humbert","year":"2021","unstructured":"Humbert M et al (2021) Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med 384:1204\u20131215","journal-title":"N Engl J Med"},{"key":"10553_CR93","unstructured":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA\u00a0(2024) A phase 2, double-blind, randomized, placebo-controlled study to evaluate the effects of sotatercept versus placebo for the treatment of combined postcapillary and precapillary pulmonary hypertension (Cpc-PH) due to heart failure with preserved ejection fraction (HFpEF). https:\/\/clinicaltrials.gov\/study\/NCT04945460. Accessed 15 June 2025"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10553-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10553-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10553-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T20:04:28Z","timestamp":1763150668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10553-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":93,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10553"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10553-8","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"13 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}